Latest Lead News

Recce Pharmaceuticals reported a 21% increase in net loss to $21.4 million for FY2025, driven by intensified R&D spending. The company secured key regulatory approvals for Phase 3 trials of its lead anti-infective gel and bolstered its financial position with significant capital raises and grants.

Botanix Pharmaceuticals posted a sharp revenue increase driven by its new hyperhidrosis treatment Sofdra, yet reported a substantial net loss reflecting heavy investment in commercialisation. The company’s strong cash position underpins its path to profitability.

Holista Colltech reports a sharp 70% reduction in net loss and an 8.6% revenue rise, driven by strong supplements sales and a landmark collagen partnership with Regenerex Pharma.

OpenLearning Limited reported a 30% revenue increase for the half-year to June 2025, driven by expanded AI-powered LMS adoption and multi-year contracts in the Philippines, while working towards break-even despite a wider loss.

Excelsior Capital Limited reports a sharp 98% drop in profit after tax for FY25 following the prior year’s $47.2 million gain from selling its CMI Electrical subsidiary. Despite this, the company declared a fully franked final dividend of 4.0 cents per share.

Decidr AI Industries Ltd has reported a dramatic turnaround with a $71.1 million profit for FY2025, driven by its strategic acquisition of Decidr.ai Pty Ltd. The company is now moving to acquire full ownership of Decidr.ai, signaling a bold push into AI software.

Perpetual Resources has launched a prospectus to enable trading of new options issued alongside a recent $1.6 million placement, aiming to unlock liquidity while outlining key risks for investors.

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Finexia Financial Group has restated its FY24 financials due to a material error in expense accruals and reduced the value of its Stayco investment by $4 million following an external valuation review.

Burgundy Diamond Mines posted a $29.5 million net loss for H1 2025, driven by operational disruptions and weaker diamond prices, leading to a temporary halt of mining at Point Lake. The company is navigating liquidity challenges with new financing arrangements while restructuring its operations.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.

Aeris Environmental Ltd reported a modest revenue increase for FY2025 but saw its operating loss widen sharply to $4.12 billion, raising concerns about its financial stability.